MedPage Today on MSN
CAR-T Drug for Myeloma Hit With New Boxed Warning
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...
CAR2119’s single-infusion approach offers cost and compliance advantages, though its competitors maintain strong commercial ...
Preclinical data support Abalos’ first-in-class approach of safely harnessing the immunostimulatory and anti-tumoral properties of ...
Artificial intelligence (XGBoost) in predicting outcomes among CAR-T therapy patients: The impact of malnutrition and comorbidities using the National Inpatient Sample (2020-2022). Engineering ...
Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the ...
Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
T-cell engagers, especially BiTEs, show promise in treating solid tumors by targeting tumor-associated antigens and redirecting T-cell activity. Tarlatamab, targeting DLL3 in SCLC, demonstrated ...
Individuals with post-COVID syndrome had higher immune cell counts after receiving exercise-based rehabilitation vs. usual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback